4.90
+0.04(+0.82%)
Currency In USD
Address
3000 Pegasus Park Drive
Dallas, TX 75247
United States of America
Phone
214 612 0000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
73
First IPO Date
September 24, 2020
| Name | Title | Pay | Year Born |
| Sean Nolan | CEO & Chairman | 1.03M | 1968 |
| Kamran Alam | Chief Financial Officer & Corporate Secretary | 676,688 | 1978 |
| Sukumar Nagendran | President, Head of Research & Development and Director | 907,175 | 1967 |
| Berge Minassian | Chief Medical Advisor of UT Southwestern Gene Therapy Program | 0 | N/A |
| Steven Gray | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | 0 | N/A |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | 0 | N/A |
| Frederick Porter | Chief of Staff & Technical Operations Officer | 0 | N/A |
| Sean McAuliffe | Chief Business Officer | 0 | N/A |
| Emily McGinnis | Chief Patient & External Affairs Officer | 0 | N/A |
| Tracy Porter | Chief People Officer | 0 | N/A |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.